Corbus Pharmaceuticals Gets a Buy Rating from Cantor Fitzgerald

By Jason Carr

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ: CRBP) yesterday and set a price target of $32. The company’s shares closed yesterday at $6.85.

According to, Piros is ranked 0 out of 5 stars with an average return of -6.2% and a 46.9% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Dimension Therapeutics Inc.

Corbus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28.

The company has a one-year high of $10.50 and a one-year low of $5.30. Currently, Corbus Pharmaceuticals has an average volume of 924.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Its produc, JBT-101 is a novel synthetic oral endocannabinoid-mimetic drug that is intended to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. The company was founded in December 2013 and is headquartered in Norwood, MA.